



ASX / MEDIA RELEASE

Monday, May 16, 2011

Strategic milestone underpins US revenue growth

USA National Sales Manager appointed to underpin substantial expansion of existing USA sales force and subsequent increase in revenues

MELBOURNE, 16th May 2011: Compumedics Limited (ASX:CMP) is pleased to announce the achievement of a major milestone, in support of its stated strategy to substantially expand the existing Compumedics sales force, with the hiring of a new USA National Sales Manager, Mr. Bob Daspit.

Mr. Daspit has more than 10 years experience in senior sales leadership roles (Director of Sales or equivalent) at three global medical device companies. Mr. Daspit has managed large sales teams and has a proven track record of exceeding sales budgets and delivering key milestones, with particular emphasis on developing national accounts.

Mr. Daspit has significant sales experience in a wide array of medical devices, with particular emphasis on neuro-diagnostics products. Neuro-diagnostics is a critical go-forward growth platform for the Company, with the recently released Neuvo® long-term EEG monitoring (LTEM) system world-wide.

Compumedics has continued to execute upon its stated USA sales force expansion strategy, in addition to its strategy to release captive product and IP value through further active strategic/alliance engagements.

The appointment of a strong and experienced sales leader in the US, being Compumedics largest market for its current product suite, is an important part of this strategy and today's announcement confirms this milestone.

Mr. Burton, Executive Chairman of Compumedics noted; "We are delighted to have Bob join the Compumedics team and look forward to a significant sales leadership contribution from him as we look to significantly expand our market share in the USA across our current product suite. The appointment of Bob is another step along the path of the Company delivering the outcomes of its stated strategy to expand the current core diagnostic business by a two to three fold increase in its sales force. Additionally, the Company will augment this organic growth with appropriate strategic partners for new market opportunities for existing products, such as home-sleep testing, as well as step-out growth opportunities, such as sleep treatment."

For further information, please contact

David Burton, PhD
CEO, Chairman
Compumedics Limited
30-40 Flockhart St
Abbotsford; Vic. 3067, Australia
Email - dburton@compumedics.com

For personal use only

About Compumedics Ltd:

Vision: Compumedics is a world leading supplier of medical technology for patient monitoring. Since 1987, Compumedics' strategy has focused on developing its core competency –Sleep Diagnostics – which has enabled the company to become one of the leaders in this growing international healthcare market. Today Compumedics has evolved into one of the world's leading suppliers of medical technology for sleep, brain and ultrasonic blood flow monitoring, with the convergence of these technologies now becoming imminent and evident. Compumedics' technologies and products are distributed to clients around the globe, helping millions of people who suffer from debilitating sleep, neurological and other healthcare problems. Each of these markets is multi-billion dollar in scope, at an early phase of evolution, with high growth expectations and Compumedics technology is uniquely positioned for imminent growth in each of these markets.

Background: Compumedics is a global, leading designer and supplier of high-tech sleep, brain, and ultrasonic blood-flow monitoring systems for sleep, neurological and other associated healthcare problems. Each of these markets is multi-billion dollar in scope, at an early phase of evolution, and with high growth expectations. Compumedics is a profitable company, uniquely positioned for imminent growth in each of these markets. Compumedics Limited was founded in **1987** by current Chairman/CEO Dr. David Burton and today is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In **1987** Compumedics established Asia Pacific's first fully computerized sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. In **1995** the company was selected to supply equipment to the US Sleep Heart Health Study, the world's largest sleep study of its kind, with over 8,000 participants scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe its products are distributed in over 50 countries. In **1998** Compumedics was awarded the overall Australian Exporter of the Year. In **2000** Compumedics was listed on the Australian Stock Exchange. In **2002**, Compumedics acquired US-based **Neuroscan** - the world's leading supplier of instruments for brain research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. In **2003** Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. In **2004**, Compumedics acquired Germany-based **DWL Elektronische GmbH**, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. In **2006**, Compumedics was awarded the Frost and Sullivan Technology Leadership award for its innovative Somté® recorder product. In **2007**, Compumedics and its Chairman were inducted into the Victorian Manufacturing Hall of Fame. In **2008** the DWL division received a top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics Compumedics sales have grown more than 4-fold from \$9 million (1999) to \$39 million (2008). In **2009** Compumedics was awarded a design award for its GRAEL® PSG/EEG premium laboratory-based product. In **2010** Compumedics was recognized by the Australian Innovation Government and Industry body as one of Australia's Top 100 Health Innovators through its' world leading devices for sleep diagnostics. **For further background please visit.**

Go-forward Mission: Stay the unique and visionary Compumedics course; expand the sales force 2-3 fold over next 2 to 3 years and release captive product and IP value through further active strategic/alliance engagements.

For further information please visit : www.compumedics.com <http://www.compumedics.com> or **contact:**

Compumedics CEO/Chairman: Dr. David Burton 61-3-8420-7300; dburton@compumedics.com.au

Bourse Communications: Mr. Rod North T: 03 9510 8309 M: 0408 670 706 E:rod@boursecommunications.com.au

Investors: CMP.ASX (ASX.COM)

For personal use only